

SCIENTIFIC PROGRAMME

DAY 1 - Friday, 20 October 2023	
MAIN HALL 08.40 - 09.00	Welcome and Introduction to EndoBridge 2023
MAIN HALL 09.00 - 11.00	
09.00 - 09.30	Approaches to diagnosis and management of hyperprolactinemia - <i>Ursula Kaiser</i>
09.30 - 10.00	Advances in the treatment of acromegaly - <i>Aj van der Lely</i>
10.00 - 10.30	Many faces of autoimmune hypophysitis - <i>Misa Pfeifer</i>
10.30 - 11.00	Advances in medical treatment for Cushing's disease - <i>John Newell-Price</i>
11.00 - 11.20	Coffee Break
11.20 - 12.50	Interactive Case Discussion Sessions
HALL A	Pituitary - <i>Ursula Kaiser, John Newell-Price</i>
HALL B	Adrenal - <i>Selma Witchel, Duarte Pignatelli</i>
HALL C	Transitional Neuroendocrinology - <i>Margaret Boguszewski, Cesar Boguszewski</i>
HALL D	Male Reproductive Endocrinology - <i>Dimitrios Goulis, Gesthimani Mintzioti</i>
12.50 - 14.00	Lunch
14.00 - 15.30	Interactive Case Discussion Sessions
HALL A	Pituitary - <i>Misa Pfeifer, Aj van der Lely</i>
HALL B	Adrenal - <i>Gary Hammer, Constantine Stratakis</i>
HALL C	Neuroendocrine Tumors - <i>Gregory Kaltsas, Djuro Macut</i>
HALL D	Female Reproductive Endocrinology - <i>Jennifer Law, Punith Kempegowda</i>
15.30 - 15.50	Coffee Break
MAIN HALL 15.50 - 17.50	
15.50 - 16.20	CAH management after transition to adult care - <i>Selma Witchel</i>
16.20 - 16.50	Advancing treatment of adults with Turner Syndrome - <i>Jennifer Law</i>
16.50 - 17.20	Diagnostic and therapeutic approach of male hypogonadism - <i>Dimitrios Goulis</i>
17.20 - 17.50	Adrenal masses - What to do: Malignant potential & function - Impact on Diagnosis/Prognosis/Therapeutics - <i>Gary Hammer</i>
DAY 2 - Saturday, 21 October 2023	
MAIN HALL 09.00 - 11.00	
09.00 - 09.30	Glucose metabolism after bariatric surgery: Implications for T2DM remission and hypoglycemia - <i>Mary Elizabeth Patti</i>
09.30 - 10.00	Fatty liver disease: A hidden complication of diabetes - <i>Carol Wysham</i>
10.00 - 10.30	Perioperative management of hyperglycemia in hospitalized patients for elective surgery - <i>Anton Luger</i>
10.30 - 11.00	Diabetes technology for people with type 2 diabetes - <i>Julia Mader</i>
11.00 - 11.20	Coffee Break
11.20 - 12.50	Interactive Case Discussion Sessions
HALL A	Diabetes - <i>Carol Wysham, Mary Elizabeth Patti</i>
HALL B	Thyroid - <i>Kristien Boelaert, Robin Peeters</i>
HALL C	Bone and Calcium - <i>Marlene Chakhtoura, Michael McClung</i>
HALL D	Obesity, Metabolism and Nutrition - <i>Luca Busetto, Barbara McGowan</i>
12.50 - 14.00	Lunch
14.00 - 15.30	Interactive Case Discussion Sessions
HALL A	Diabetes - <i>Anton Luger, Julia Mader</i>
HALL B	Thyroid - <i>Jennifer Sapos, Megan Haymart</i>
HALL C	Bone and Calcium - <i>Aliya Khan, Michael Collins</i>
HALL D	Obesity, Metabolism and Nutrition - <i>Volkan Yumuk, Dilek Yazici</i>
15.30 - 15.50	Coffee Break
MAIN HALL 15.50 - 17.50	
15.50 - 16.20	Updates on thyroid nodule risk stratification - <i>Jennifer Sapos</i>
16.20 - 16.50	Challenges in optimizing treatment of low-risk thyroid cancer. - <i>Megan Haymart</i>
16.50 - 17.20	Hyperthyroidism in 2023 - <i>Kristien Boelaert</i>
17.20 - 17.50	Subclinical hypothyroidism: To treat or not to treat - <i>Robin Peeters</i>
DAY 3 - Sunday, 22 October 2023	
MAIN HALL 09.00 - 11.00	
09.00 - 09.30	Sarcopenic obesity: diagnosis and management - <i>Luca Busetto</i>
09.30 - 10.00	An update in obesity pharmacotherapy in 2023 - <i>Barbara McGowan</i>
10.00 - 10.30	Surgery and pharmacotherapy combinations in obesity management - <i>Alex Miras</i>
10.30 - 11.00	New lipid lowering therapies: Which to use when? - <i>Lale Tokgözoğlu</i>
11.00 - 11.20	Coffee Break
MAIN HALL 11.20 - 13.20	
11.20 - 11.50	Evaluation and management of hypoparathyroidism - <i>Aliya Khan</i>
11.50 - 12.20	Endocrine disorders of FGF23 - <i>Michael Collins</i>
12.20 - 12.50	Impact of vitamin D supplementation on health outcomes - <i>Ghada El-Hajj Fuleihan</i>
12.50 - 13.20	Secondary osteoporosis - <i>Michael McClung</i>
13.20 - 13.30	Closing comments and adjourn

